Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union.
Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses within Africa
July 21, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022